The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Specific Impairment of Human Platelet P2Y AC ADP Receptor–Mediated Signaling by the Antiplatelet Drug Clopidogrel
Open accessAbstract
Abstract —Clopidogrel is an effective new antiplatelet agent useful for the treatment of ischemic cerebrovascular, cardiac, and peripheral arterial disease. However, the mechanism of clopidogrel action is not well understood, although it is known to inhibit ADP-evoked platelet aggregation. In the current study, the effect of clopidogrel on recently identified human platelet ADP receptors and their signaling pathways was investigated by using platelets from clopidogrel-treated subjects, 6 healthy volunteers (2 females and 4 males) who received 75 mg of clopidogrel daily for 7 days. Blood was taken and various platelet receptor signaling pathways were analyzed before treatment, after 7 days of medication, and 4 weeks after treatment had ceased. Platelet tests included the analysis of aggregation, rapid calcium influx, calcium mobilization from intracellular stores, adenylyl cyclase, and phosphorylation of vasodilator-stimulated phosphoprotein (VASP). The data indicate that clopidogrel does not affect those platelet ADP receptors coupled to cation influx (P2X1 ADP receptors) or calcium mobilization (P2Y1 ADP receptors). In contrast, clopidogrel treatment specifically impairs the ADP receptor coupled to G i /adenylyl cyclase (P2Y AC ADP receptors). Clopidogrel abolishes the inhibitory P2Y AC receptor–mediated ADP effects on prostaglandin E 1 –stimulated, cAMP-dependent phosphorylation of VASP without affecting epinephrine, thrombin, and thromboxane signaling. VASP phosphorylation is known to be closely correlated with the inhibition of platelet and fibrinogen receptor (glycoprotein IIb/IIIa) activation. Therefore, inhibition of the platelet P2Y AC ADP receptor and its intracellular signaling, including decreased VASP phosphorylation, is suggested as a molecular mechanism of clopidogrel action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
The clinical implications of endothelial dysfunction
Widlansky, M. E., Gokce, N., Keaney, J. F., & Vita, J. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00994-x · Cited by 1,749
Lau, W. C., Waskell, L. A., Watkins, P. B., Neer, C. J., Horowitz, K., Hopp, A. S., Tait, A. R., Carville, D. G. M., Guyer, K. E., & Bates, E. R. (2003) · Circulation · doi:10.1161/01.cir.0000047060.60595.cc · Cited by 688
Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis
Gurbel, P. A., Bliden, K. P., Samara, W., Yoho, J. A., Hayes, K., Fissha, M. Z., & Tantry, U. S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.056 · Cited by 536
Resistance to clopidogrel: A review of the evidence
Nguyen, T. A., Diodati, J. G., & Pharand, C. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.034 · Cited by 520
Lau, W. C., Gurbel, P. A., Watkins, P. B., Neer, C. J., Hopp, A. S., Carville, D. G. M., Guyer, K. E., Tait, A. R., & Bates, E. R. (2004) · Circulation · doi:10.1161/01.cir.0000112378.09325.f9 · Cited by 487
Metadata
- Authors
- Geiger, J., Brich, J., Hönig-Liedl, P., Eigenthaler, M., Schanzenbächer, P., Herbert, J. M., & Walter, U.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1999-08
- Volume
- 19
- Issue
- 8
- Pages
- 2007-2011
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2149238031
- Cited by
- 212
- References
- 1
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific Impairment of Human Platelet P2Y AC ADP Receptor–Mediated Signaling by the Antiplatelet Drug Clopidogrel. https://app.cochat.ai/papers/10.1161/01.atv.19.8.2007
- The paper
- Geiger, J., Brich, J., Hönig-Liedl, P., Eigenthaler, M., Schanzenbächer, P., Herbert, J. M., & Walter, U. (1999). Specific Impairment of Human Platelet P2Y AC ADP Receptor–Mediated Signaling by the Antiplatelet Drug Clopidogrel. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.19.8.2007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.